HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME: Take the course for this article: Volume 64, Number 5, March 08, 2005 Data Supplement Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Salinsky, M. C. Articles by Dodrill, C. B. Search for Related Content PubMed PubMed Citation Articles by Salinsky, M. C. Articles by Dodrill, C. B. Related Collections All Neuropsychology/Behavior All Epilepsy/Seizures Antiepileptic drugs

Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers

From the Oregon Health and Science University (Drs. Salinsky, Spencer, Oken, and Landry) and Portland Veterans Affairs Medical Center (Dr. Storzbach), Portland, OR, and University of Washington School of Medicine (Dr. Dodrill), Seattle.

Address correspondence and reprint requests to Dr. M.C. Salinsky, OHSU Epilepsy Center, 3181 SW Sam Jackson Park Rd., CDW-3, Portland, OR 97201; e-mail: Salinsky{at}OHSU.edu

Objective: To evaluate the cognitive effects of topiramate (TPM) and gabapentin (GBP).

Methods: Forty healthy volunteers were randomized to a 12-week course of TPM, GBP, or placebo. Doses were gradually escalated over 10 weeks to a maximum of 400 mg/day of TPM or 3,600 mg/day of GBP or to the highest tolerated dose. Subjects were interviewed and examined biweekly. Cognitive testing was performed prior to initiating the drug and again 12 weeks later, at least 2 weeks after achieving plateau dosing. For each subject and cognitive measure, test–retest Z scores were calculated based on regression equations derived from 73 healthy volunteers. Group comparisons utilized the Wilcoxon test.

Results: There were significant TPM vs GBP and TPM vs placebo differences in test–retest Z scores for four of six target cognitive measures (Digit Symbol, Story Recall, Selective Reminding, Controlled Oral Word Association), always indicating worse retest performance for subjects receiving TPM. Overall, 12 of 24 cognitive measures were similarly affected. TPM effects were large, and several target measures averaged >2 SD of negative change. One measure was significantly affected by GBP.

Conclusions: Topiramate (TPM) impaired cognitive test performance, whereas gabapentin had minimal effects. The effects of TPM were of sufficient magnitude potentially to affect daily and occupational function.

This article has been cited by other articles:

				E. Wirrell, E. M. S. Sherman, R. Vanmastrigt, and L. Hamiwka Deterioration in Cognitive Function in Children With Benign Epilepsy of Childhood With Central Temporal Spikes Treated With Sulthiame J Child Neurol, January 1, 2008; 23(1): 14 - 21. [Abstract] [PDF]

				D. F. Hayes Follow-up of Patients with Early Breast Cancer N. Engl. J. Med., June 14, 2007; 356(24): 2505 - 2513. [Full Text] [PDF]

				D. Blum, K. Meador, V. Biton, T. Fakhoury, B. Shneker, S. Chung, K. Mills, A. Hammer, and J. Isojarvi Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy Neurology, August 8, 2006; 67(3): 400 - 406. [Abstract] [Full Text] [PDF]

				Is Thin Better Than Smart? Cognitive Effects of an Anticonvulsant Journal Watch Psychiatry, April 6, 2005; 2005(406): 1 - 1. [Full Text]

				Effects of Topiramate on Cognition Journal Watch (General), April 5, 2005; 2005(405): 3 - 3. [Full Text]

				Minerva BMJ, March 26, 2005; 330(7493): 738 - 738. [Full Text] [PDF]